Trial Profile
A prospective single-center, open-label, randomized,comparative study to evaluate whether sitagliptin can decrease intrahepatic lipid accumulation in diabetic patients with non fatty liver disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2015
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Metformin
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 28 Jul 2015 New trial record
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.